NCAA Sickle Cell Trait Screening

Timeline

1. Sep 25, 2006A Rice freshman football player dies after a team workout.
2. Sep 2008His family sues Rice and the NCAA.
3. Jun 2009The lawsuit is settled; the NCAA agrees to recommend testing.
4. Apr 13, 2010NCAA Division I adopts mandatory screening with a waiver option.
5. 2012The American Society of Hematology opposes mandatory screening.
6. 2012A study finds a 37-fold higher risk of exertional death in Division I football players with the trait.

The ethical issues

• Genetic screening: testing as a condition of participation.
• Consent: whether waivers are meaningful.
• Race: a policy affecting mostly Black athletes.
• Duty of care: universal precautions versus targeted screening.
• Liability: protecting institutions or athletes.

Stakeholders

Stakeholder	Interests & obligations
Athletes with sickle cell trait	Safety, privacy and nondiscrimination.
All athletes	Safe training conditions.
Universities and coaches	Duty of care and liability.
NCAA	Policy and legal exposure.
Medical organizations	Evidence-based practice.
Families	Information and protection.

The case

Sickle cell trait means carrying one copy of the gene that causes sickle cell disease. It is found in 8 to 10% of African Americans and is usually harmless.^[4] Rarely, during intense exertion, especially in heat or dehydration, red blood cells can sickle and cause muscle breakdown and collapse.^[1]

Background

The trait is common in populations with African ancestry for an evolutionary reason: carriers have significantly lower death rates from malaria, especially the most dangerous form.^[1] That history helps explain why a screening rule that is neutral on its face falls far more heavily on Black athletes.^[1][4]

A sickling collapse looks different from ordinary heat illness. It comes on slowly, after cramping, weakness, general aches and fatigue. The cramping is usually less intensely painful than heat cramps, without the locked muscles, and is accompanied by weakness.^[1] Preventive measures include proper hydration, gradual acclimatization to heat, humidity and altitude, and a slow build-up of exertion over several weeks.^[1]

The rules and governance

The NCAA rule is built on informed choice with a liability shield. Athletes must either be tested, show earlier results or sign a waiver releasing their school from liability.^[1][2] The NCAA has also worked with the American College of Sports Medicine on a joint statement warning athletes about the trait and its risk factors, and encourages athletes to learn their status.^[1]

The rule came from a legal settlement, not a medical consensus. That is why the American Society of Hematology could object that the policy went beyond the evidence, while the NCAA defended it as part of its duty of care.^[3][4]

A death at Rice

A 19-year-old Rice University freshman football player became ill during a team workout and died on September 25, 2006. An autopsy concluded that his death was caused by acute exertional rhabdomyolysis associated with sickle cell trait.^[2] At the time, the NCAA did not require testing. A 2006 survey found that 21% of universities tested for the trait; Rice did not.^[3]

His parents sued Rice and the NCAA in 2008. In a June 2009 settlement, the NCAA agreed to recommend testing, and Rice agreed to submit legislation making it mandatory.^[3] His mother said, “You have to know your status and the precautions.”^[3]

The policy

On April 13, 2010, NCAA Division I adopted a rule, effective for 2010–11, requiring athletes to be tested unless they show prior results or sign a waiver releasing their institution from liability.^[2] The measure was adopted by the Division I Legislative Council. It grew out of legislation sponsored by Conference USA, Rice’s conference, as part of the settlement with the player’s parents. Rice said it already followed the National Athletic Trainers’ Association’s sickle cell guidelines and that most top-division universities were by then screening for the trait.^[2] As part of the settlement, Rice also created an athletic scholarship in the player’s memory.^[2] USA Today reported that the trait had been linked to at least nine of 21 deaths of college football players since 2000.^[3]

The evidence

A 2012 study in the British Journal of Sports Medicine reviewed sudden deaths of NCAA athletes from 2004 to 2008. All five deaths associated with the trait occurred in Black Division I football players. The risk of exertional death for Division I football players with the trait was 1 in 827, 37 times higher than for those without it. The authors called for more research on whether screening reduces deaths.^[5] The study’s denominator was about 2 million athlete-years, so the absolute numbers behind the 37-fold figure were small.

The objection

The American Society of Hematology said in 2012 that it “does not support testing or disclosure of sickle cell trait status as a prerequisite for participation in athletic activities,” calling it unjustified by current evidence and “not consistent with good medical practice or established principles of public health ethics.”^[4] It noted that rhabdomyolysis and exertional collapse also occur in people without the trait, and urged universal measures, such as heat acclimatization, hydration and work-rest cycles, that it said had lowered deaths for all U.S. Army trainees.^[4]

The military experience became central to the dispute. A 2016 study in the New England Journal of Medicine followed 47,944 Black soldiers on active duty in the U.S. Army between 2011 and 2014. All had been tested for the trait and were subject to the Army’s universal exertional-injury precautions.^[6] The trait was associated with a 54% higher adjusted risk of exertional rhabdomyolysis, an effect similar in size to smoking or a body-mass index of 30 or more. It was not associated with a higher risk of death (hazard ratio 0.99).^[6] The authors concluded that the trait “was not associated with a higher risk of death than absence of the trait,” while noting the higher risk of muscle breakdown.^[6] The study did not test whether screening adds anything once such precautions are in place. Experts also stressed that screening alone accomplishes nothing without education and changes in training.^[3]

Aftermath

The first direct test of the NCAA rule came in 2020. Researchers including the authors of the 2012 study reviewed NCAA athlete deaths from 2000 to 2019, covering about 8.3 million athlete-years.^[7] Among Division I football players, deaths associated with the trait fell from nine before the August 2010 legislation to one after it, an 89% reduction in risk. The rate fell from 1 in 28,145 athlete-years to 1 in 250,468.^[7] Among Black Division I football players, the rate fell from 1 in 12,519 to 1 in 118,464.^[7] Outside football such deaths were rare. Across all NCAA athletes the decline, from ten deaths to two, was not statistically significant.^[7]

The authors were careful about what the numbers showed. The NCAA rule had come with an educational campaign for athletes, coaches and medical staff, and they wrote that “it is unclear whether the decrease is related to screening for SCT, education, or both.”^[7] They called it “the first evidence that NCAA SCT legislation may save lives.”^[7] That answer suits neither side completely. The deaths the rule was meant to prevent did fall, but the evidence cannot separate the label from the safeguards, so the hematologists’ question remains open: whether universal precautions alone would have done as well without singling out athletes by a genetic trait.^[4][6][7]

The core dilemma

Screening can identify athletes at elevated risk and prompt precautions. But it applies genetic testing to athletic participation, mostly affects Black athletes, offers a waiver that may protect institutions more than athletes, and may distract from making training safe for everyone. What best fulfills the duty of care?

Competing values

• Targeted protection vs. universal precautions.
• Knowledge vs. privacy and stigma.
• Institutional liability vs. athlete welfare.
• Family advocacy vs. professional medical consensus.

Strongest arguments

For screening: the elevated risk is real, knowing one’s status enables precautions, and families have argued it could have saved lives.

Against mandatory screening: universal precautions protect everyone, genetic screening risks discrimination, and waivers shift responsibility to athletes.

Applying the frameworks

Ethics of care

The care lens begins with athletes like the Rice freshman, whose deaths might have been prevented if staff had recognized the risk. It asks what attentive care requires: knowing the athlete, adjusting training, and responding quickly to early signs. It favors screening only if it leads to better care, not if it simply shifts liability.

Rights

A rights lens emphasizes informed consent, privacy and protection from discrimination. Requiring genetic information as a condition of play, with a waiver as the only alternative, raises questions about coercion and stigma, especially for Black athletes who are far more likely to carry the trait.

Utilitarian

Consequentialists compare outcomes: does screening plus targeted precautions save more lives than universal precautions alone, and at what cost in stigma or exclusion? The Army’s experience with universal measures and the BJSM data both feed into the calculation.

Walk it through: the Simple Decision Model

1. Spot the issue. You are a team physician at a Division I school in 2010 implementing the new screening rule. The stakeholders include athletes, coaches, athletic trainers, parents, and the school. The codes in play are the NCAA rule, medical ethics and privacy law.
2. Gather facts. What does the evidence say about the risks and about prevention? How will results be used, and who will see them?
3. Test options. Options: (a) test, record and leave training unchanged; (b) test and adjust training for athletes with the trait; (c) also adopt universal heat and exertion precautions for all athletes. Weigh safety against privacy and stigma.
4. Check codes and law. Are you protecting athletes or the institution? Are waivers being signed with real understanding?
5. Decide and document. Record the policy, consent process and training changes.
6. Communicate and follow up. Communicate clearly with athletes and coaches about what the trait means, and review the program regularly.

What’s settled and what’s contested

• Settled: the policy’s origin; the elevated relative risk in Division I football.
• Contested: whether screening reduces deaths; whether it should be mandatory.

Why this case matters

The case shows how genetics, race, consent and liability intersect in athlete safety policy.

Key terms

Paternalism (hard and soft)

Restricting someone’s choices for their own good. Hard paternalism overrides competent, informed adults; soft paternalism steps in when information or autonomy is compromised.

Consent and autonomy

Whether people have agreed freely and with full information, and whether their right to make their own choices is respected.

Duty of care

The responsibility of coaches, organizations and institutions to protect the health, safety and well-being of those in their charge. It is not a license for total control.

Non-maleficence

The duty to avoid causing harm, often paired with care ethics when setting safety rules.

Definitions from the Ethics Cases glossary.

Discussion questions

1. Should athletes be required to learn their sickle cell trait status?
2. Is a waiver a genuine choice for a scholarship athlete?
3. Does a policy that mostly affects Black athletes raise equity concerns, even if intended to protect them?
4. Are universal precautions sufficient without screening?
5. Who should bear responsibility when an athlete dies during conditioning?

Sources

1. Sickle cell trait — Wikipedia
2. NCAA adopts regulation on sickle cell screening — Rice University News
3. Lawsuit prompts NCAA to screen athletes for sickle cell — USA Today
4. Statement on Screening for Sickle Cell Trait and Athletic Participation — American Society of Hematology
5. Sickle cell trait associated with a RR of death of 37 times in National Collegiate Athletic Association football athletes — British Journal of Sports Medicine
6. Sickle Cell Trait, Rhabdomyolysis, and Mortality among U.S. Army Soldiers (Nelson et al., 2016) — New England Journal of Medicine
7. Sudden Death Associated With Sickle Cell Trait Before and After Mandatory Screening (Buchanan et al., 2020) — Sports Health